Intelligence workbench
Historical account-planning preview
Project record · 10187982
CHROMASKIN: Minimally-Invasive Interstitial Fluid Sensing Materials for Semi-Permanent Dermal Readouts
Recipient: CIPHERX TECHNOLOGIES LTD
Verified official record
SOURCE FACTS
Imported fields from the dated official snapshot. The displayed source does not establish a procurement plan or unrestricted spending.
- Recipient organisation
- CIPHERX TECHNOLOGIES LTD
- Project reference
- 10187982
- Funder
- Innovate UK
- Programme
- National Materials Innovation Programme: Feasibility Studies
- Award value
- £99,780
- Project dates
- 1 May 2026 – 31 Jan 2027
- Imported sector
- Advanced Manufacturing Lvl3
- Postcode area
- W (W12 7RZ)
- Project status
- Live
- Source data quality
- Description present in snapshot
Derived analysis
GRANTSIGNAL INFERENCES
Commercial inference — not stated procurement intention.
Possible supplier-fit category: PROTOTYPING
Evidence from description: “prototype”
The project description mentions this activity; it does not state an intent to buy from a supplier.
This is a categorisation of wording in the project description, not a claim that the recipient intends to buy, tender, appoint, or contact any supplier.
Official project description
CHROMASKIN is an innovative dermal biosensing technology that enables people to monitor key health markers using a small, painless microneedle patch. When placed on the skin, the microneedle penetrate the skin dissolve and deposit tiny colour-changing particles into the dermis. These particles interact with the body's interstitial fluid and change colour in response to important metabolic indicators such as acidity (pH), glucose or others. The colour change is visible on the skin for several days and can be measured using an ordinary smartphone camera. This allows users to track changes in their metabolic health without finger-pricks, electronics, wearables, or implants. CHROMASKIN represents a completely new approach to health monitoring, using materials-based sensing rather than electronic hardware. The project will develop and test new sensing materials, integrate them into dissolving microneedle patches, and evaluate their performance using laboratory skin models. It will also begin the development of a simple phone-based tool to read and interpret the colour signals. By the end of the project, the team aims to have a functional prototype suitable for further development and regulatory planning. CHROMASKIN is being developed by CipherX Technologies, a UK company specialising in microneedle devices and advanced polymer materials. The project aligns with national priorities in preventive healthcare, diagnostics innovation, and high-value manufacturing. If successful, this technology could transform access to low-cost metabolic monitoring for individuals, healthcare providers, and researchers. It could support early identification of health risks, reduce reliance on invasive tests, and provide a minimally intrusive alternative for metabolic sensing.
Provenance & data availability
- Snapshot imported
- 10 Aug 2026, 07:53 UTC
- Source publication/snapshot date
- 2026-07-06
- Source
- Innovate UK funded-project workbook via UKRI
- Company matching
- Not assessed in this demo. A supplied company number may exist in the source, but it has not been independently verified against Companies House.
The validation found that the snapshot first-seen time followed project starts in the reviewed sample. This demo is therefore historical research only, not a new-award, current-status, or project-timing service.